Flunitrazepam Oxidative Metabolism in Human Liver Microsomes: Involvement of CYP2C19 and CYP3A4
Overview
Toxicology
Authors
Affiliations
The aims were to examine the kinetics of the oxidative metabolism of flunitrazepam in vitro when flunitrazepam was dissolved in dimethylformamide and acetonitrile, and to determine which cytochrome P450 isoform(s) are involved. The kinetics of the formations of 3'-hydroxyflunitrazepam and desmethyl-flunitrazepam were non-linear and best estimated using the Hill equation. Inhibition of their formation was studied using specific chemical inhibitors, expressed enzyme systems and specific antibodies. Ks, Vmax, Clmax and n (slope factor) for the formation of 3'-hydroxyflunitrazepam and desmethylflunitrazepam had ranges of 165-338 and 179 391 microM, 22-81 and 3-10 nmol x mg protein(-1) x h(-1), 6-17 and 0.9-1.9 microl x mg protein(-1) x h(-1), and 2.3-3.6 and 1.6-2.6 respectively when dimethylformamide was the organic solvent. When acetonitrile was the solvent, Ks, Vmax, Clmax and n (slope factor) for the formation of 3'-hydroxyflunitrazepam and desmethylflunitrazepam had ranges of 173-231 and 74-597 microM, 35-198 and 2.7-48 nmol.mg protein(-1) x h(-1), 1347 and 0.7-6.3 microl.mg protein(-1) x h(-1), and 1.5-3.6 and 1.1-2.7 respectively. CYP2C19, CYP3A4 and CYP1A2 mediated the formation of both 3'-hydroxyflunitrazepam and desmethylflunitrazepam. Investigators need carefully to consider the choice of organic solvent to avoid false CYP identification.
Pharmaceutical Excipients and Drug Metabolism: A Mini-Review.
Patel R, Barker J, ElShaer A Int J Mol Sci. 2020; 21(21).
PMID: 33153099 PMC: 7662502. DOI: 10.3390/ijms21218224.
Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam.
Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S Forensic Toxicol. 2017; 35(1):1-10.
PMID: 28127407 PMC: 5214877. DOI: 10.1007/s11419-016-0338-5.
Pharmacogenetics of anxiolytic drugs.
Tiwari A, Souza R, Muller D J Neural Transm (Vienna). 2009; 116(6):667-77.
PMID: 19434367 DOI: 10.1007/s00702-009-0229-6.
Hutchinson M, Menelaou A, Foster D, Coller J, Somogyi A Br J Clin Pharmacol. 2004; 57(3):287-97.
PMID: 14998425 PMC: 1884456. DOI: 10.1046/j.1365-2125.2003.02002.x.
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z, Zhao X, Shin J, Flockhart D Clin Pharmacokinet. 2002; 41(12):913-58.
PMID: 12222994 DOI: 10.2165/00003088-200241120-00002.